ArticleCancers2014
Glioblastoma multiforme: a look inside its heterogeneous nature.
Article in Cancers, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 108 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
108 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Tracing the origins of glioblastoma by investigating the role of gliogenic and related neurogenic genes/signaling pathways in GBM development: a systematic review.World journal of surgical oncology · 2022Pooled it
- Potential role of microRNAs as biomarkers in human glioblastoma: a mini systematic review from 2015 to 2020.Molecular biology reports · 2021Pooled it
- Anti-epidermal growth factor receptor therapy for glioblastoma in adults.The Cochrane database of systematic reviews · 2020Pooled it
- Leveraging single-cell and spatial omics for brain tumour insights to improve therapeutic strategies.Molecular brain · 2026Review
- Dualsteric Agonist for M2 Muscarinic Receptor Causes Oxidative Stress and Mitochondrial Alteration in Human Glioblastoma Cancer Stem Cells.Journal of neurochemistry · 2026Article
- Tumor habitat analysis using multiparametric MRI as a noninvasive correlate of longitudinal changes in telomerase activity in recurrent IDH-wildtype glioblastoma.Scientific reports · 2026Article
- Integrating single-cell transcriptomics with deep learning for glioblastoma treatment.Frontiers in genetics · 2026Review
- Effect of chemotherapeutic drugs and cytochalasin B on tunneling nanotubes in U87 MG cells.BMC cancer · 2025Article
- Selective regulation and cellular metabolism by the lactate transporter MCT4 in GBM.Medical oncology (Northwood, London, England) · 2025Article
- Spatial Mapping of Glioblastoma Infiltration: Diffusion Tensor Imaging-Based Radiomics and Connectomics in Recurrence Prediction.Brain sciences · 2025Review
- Deciphering the dose-dependent effects of thymoquinone on cellular proliferation and transcriptomic changes in A172 glioblastoma cells.PloS one · 2025Article
- Patient-derived tumor organoids mimic treatment-induced DNA damage response in glioblastoma.iScience · 2024Article
- Ouroboros: cross-linking protein expression perturbations and cancer histology imaging with generative-predictive modeling.Bioinformatics (Oxford, England) · 2024Article
- Patient-Derived Microphysiological Systems for Precision Medicine.Advanced healthcare materials · 2024Review
- Characterization of purinergic signaling in tumor-infiltrating lymphocytes from lower- and high-grade gliomas.Purinergic signalling · 2024Article
- Molecular Targeted Therapies in Glioblastoma Multiforme: A Systematic Overview of Global Trends and Findings.Brain sciences · 2023Review
- Article
- Cell Membrane Sialome: Sialic Acids as Therapeutic Targets and Regulators of Drug Resistance in Human Cancer Management.Cancers · 2023Review
- 3D Porous Scaffold-Based High-Throughput Platform for Cancer Drug Screening.Pharmaceutics · 2023Article
- Ultra High-plex Spatial Proteogenomic Investigation of Giant Cell Glioblastoma Multiforme Immune Infiltrates Reveals Distinct Protein and RNA Expression Profiles.Cancer research communications · 2023Article
48 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heterogeneity is a hallmark of tumors and has a crucial role in the outcome of the malignancy, because it not only confounds diagnosis, but also challenges the design of effective therapies. There are two types of heterogeneity: inter-tumor and intra-tumor heterogeneity. While inter-tumor heterogeneity has been studied widely, intra-tumor heterogeneity has been neglected even though numerous studies support this aspect of tumor pathobiology. The main reason has been the technical difficulties, but with new advances in single-cell technology, intra-tumor heterogeneity is becoming a key area in the study of cancer. Several models try to explain the origin and maintenance of intra-tumor heterogeneity, however, one prominent model compares cancer with a tree where the ubiquitous mutations compose the trunk and mutations present in subpopulations of cells are represented by the branches. In this review we will focus on the intra-tumor heterogeneity of glioblastoma multiforme (GBM), the most common brain tumor in adults that is characterized by a marked heterogeneity at the cellular and molecular levels. Better understanding of this heterogeneity will be essential to design effective therapies against this devastating disease to avoid tumor escape.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.